This is a paid advertisement on behalf of sponsor FendX Technologies Inc.
Beyond Drugs and Medical Procedures
It’s neither a groundbreaking pharmaceutical nor a cutting-edge surgical technique, yet it stands poised to disrupt a market projected to reach $7.6 billion by 2025 [1]. Consider a technological innovation that may contribute to a healthcare issue costing the U.S. alone a couple of billion dollars annually in direct medical expenses. This is a pressing problem that this emerging technology aims to tackle, offering an innovative approach to a longstanding challenge.
An Opportunity: Providing a Potential Solution to a Problem Difficult to Control
In the current scenario there is a technology that could be an opportunity to address a costly problem that affects approximately 1.7 million people and claims countless lives each year in the United States alone [2]. The direct medical costs of this issue are estimated to be on the order of $28 billion, not to mention the broader societal costs such as lost productivity and reduced workforce efficiency. The market is ripe for innovative solutions.
The Solution: A Paradigm Shift in Microbial Control on Surfaces
What if the answer doesn’t lie in killing these potentially lethal microbes after they’ve settled on surfaces, but in preventing their adherence from the outset? A pioneering nanotechnology is set to redefine how we may approach this pervasive challenge, offering a strategy that could significantly reduce microbial transmission, save lives and cut healthcare costs.
FendX Technologies Inc.: Addressing the Spread of Healthcare-Associated Infections Through Nanotechnology
FendX Technologies Inc. (CSE: FNDX, OTC: FDXTF) is engaged in the development of nanotechnology solutions aimed at reducing the spread of Healthcare-Associated Infections (HAIs). FendX is collaborating with McMaster University and other partners to develop film and spray protective coatings to address this healthcare issue.
Unique Technological Approach: Preventative Measures in Microbial Control
Contrary to existing antimicrobial coatings, which function by eliminating microorganisms upon contact over some adequate duration of time, the technology developed by FendX takes a preventative approach. Utilizing nanotechnology to develop film and spray protective coatings that prevent microbial adherence to surfaces, thereby minimizing the potential for transmission. This is a significant departure from reactive coating surfaces in the market, offering a proactive method for reducing the occurrence and spread of HAIs.
REPELWRAP™ film, is FendX’s lead product in development and is with their manufacturer who is gearing up to conduct pilot runs on their commercial manufacturing line to create intermediate films for testing. FendX is also developing a spray-based product using their patent-pending nanotechnology. This spray offers the same preventative measures against microbial adherence and has the potential to be more versatile and easier-to-apply to surfaces. It not only demonstrates the same repelling properties but also effectively inactivates any residual microorganisms on the coated surface.
Market Opportunity: Beyond Healthcare into Other High Traffic Industries
FendX is focused on healthcare settings, but is also exploring potential applications in other multiple billion high-traffic industries. It is anticipated that FendX’s future protective coatings can be applied to various high-touch surfaces: from bed rails and IV poles in healthcare to potential handrails in public transport systems to door handles in restaurants and public bathrooms. Given that the technology inhibits microbial adherence, it has the potential to significantly reduce the spread of pathogens in virtually any setting where human interaction with surfaces occurs. This broad applicability signifies that the market opportunity could be vastly larger than the projected $7.6 billion for antimicrobial coatings by 2025, opening doors to various industries and settings.
The potential versatility of the technology is furthered by FendX’s development of a spray product, which could extend its applicability. Imagine a spray that could be applied not just in healthcare settings but in schools, public transportation, and various other high-traffic areas and may expand the market opportunity.
Product Development and Partnerships: Advancing Toward Commercialization
FendX Technologies is currently in the development stage of its lead product, REPELWRAP™ film, a surface coating that embodies the company’s groundbreaking nanotechnology. The scale-up development process is supported by a partnership with Dunmore International Inc., a globally recognized manufacturer of engineered coated and laminated films who will be instrumental in advancing FendX’s ability to move closer to commercial production, assuming success of its pilot runs.
While REPELWRAP™ film is in the advanced stages of development, FendX is also actively working on a spray-on version of REPELWRAP™ film that embodies the similar innovative nanotechnology. The spray product is currently in the research phase and promises to be another potential revolutionary application of their groundbreaking approach.
Investment Considerations: Factors That Distinguish FendX Technologies
Several aspects make FendX Technologies a notable investment opportunity:
Market Disruption: The company’s innovative nanotechnology to create surface coatings to reduce the spread of microbes on surfaces offers a novel approach compared to other antimicrobial film coatings.
Attractive Valuation: FendX has the potential to enter and compete in a $3.7 billion antimicrobial market.
Inflection Point: The company has recently signed a development stage agreement with Dunmore International Inc., signaling a transition from research to assessing commercial scale-up. A key milestone for FendX Technologies to advance toward a commercial path.
Additional Factors for Consideration
Diverse Market Potential: Beyond healthcare, the technology holds promise for application in multiple sectors, from public transport to hospitality, expanding its market reach.
Experienced Management Team: The company is guided by professionals with a wealth of experience in the medical and technology sectors, providing a strong foundation for market penetration.
Strong Intellectual Property: FendX Technologies is building a robust portfolio of patent-pending intellectual property that will offer competitive advantages and protect its technological innovations.
Expanding Product Range: The development of a spray-based product signifies FendX Technologies’ commitment to innovation and market adaptation. The spray offers a more versatile application, potentially increasing market share
Positive Industry Outlook: Meeting a Growing Demand
The increasing concerns over public health and hygiene are expected to fuel a growing demand for effective antimicrobial and antiviral solutions. The industry outlook is promising, and FendX Technologies’ innovative technology stands well-positioned to capitalize on this upward trend. The company’s preventative approach aligns well with the market’s shift toward more sustainable, long-term solutions to healthcare challenges.
FendX Technologies a Beacon of Innovation in Healthcare
FendX Technologies presents a revolutionary approach to tackling the persistent and costly issue of Healthcare-Associated Infections. Its pioneering nanotechnology has the potential to shift the paradigm from reactive to proactive microbial control. While the initial focus is on healthcare settings, the broad applicability of the technology opens avenues for market expansion into various sectors. Coupled with a strong intellectual property portfolio and an experienced management team, FendX Technologies offers a compelling investment opportunity for those looking to contribute to and/or potentially capitalize on meaningful change in healthcare and beyond via nanotechnology innovation.
Bill McClain – Editor of The Momentum Letter
About the author.
The Momentum Letter operates The Free Trade Report
With the dearth of easy-to-access data on company share lock-up agreements and dates, The Momentum Letter issues “The Free Trade Report” to members highlighting key share unlock dates for companies in the microcap and small cap space. To gain access to the “The Free Trade Report” database sign-up today.
Significant Past Unlocks in the last 90 days (6 of Many…)
| Ticker | Locked Shares | Unlock Date | Share Price on Unlock Date | Current Share Price | Return % Since Unlock Date | % Float Increase |
|---|---|---|---|---|---|---|
| TONY | 1,312,946 | 02/01/2024 | 0 | 0.70 | 0 | 29.39 |
| NPRA | 12,201,100 | 01/30/2024 | 0 | 0.05 | 0 | 60.11 |
| GTTX | 6,066,308 | 03/30/2024 | 0.05 | 0.05 | 0 | 20.24 |
| BRCO | 1,750,000 | 02/04/2024 | 0 | 0.00 | 0 | 23.38 |
| STK | 5,200,000 | 02/15/2024 | 0.27 | 0.25 | -7.41 | 39.01 |
| WO | 3,210,000 | 04/23/2024 | 0.11 | 0.08 | -27.27 | 98.47 |
Get access to all past stock unlock data join the Free Trade Report (it’s free! )
Upcoming Unlocks in the next 90 days (6 of Many…)
| Ticker | Locked Shares | Unlock Date | Current Share Price | % Float Increase |
|---|---|---|---|---|
| GFCO | 9,028,010 | 05/08/2024 | 0.15 | 19.91 |
| ZOG | 12,726,749 | 07/16/2024 | 0.14 | 15.23 |
| PLNK | 2,243,424 | 07/02/2024 | 0.08 | 14.48 |
| MARY | 4,111,025 | 05/20/2024 | 0.01 | 10.51 |
| BIOV | 36,783,334 | 05/02/2024 | 0.08 | 70.74 |
| BIOV | 16,716,666 | 06/10/2024 | 0.08 | 18.83 |
Get access to all upcoming stock unlock data join the Free Trade Report (it’s free! )
Unlock your access to more companies and more tools by joining “The Free Trade Report”. The Momentum Letter will deliver weekly updates such as when new companies are added to the database, new unlock dates approach and recent market impacting unlocks along with other valuable information to your inbox. You can login here or visit the registration page to create your account. (it’s free!)
Disclaimer
The Momentum Letter is a marketing partner which has received
compensation to direct traffic to this coverage. Full Disclaimer
FendX Technologies Inc. General Disclaimer
This article contains certain forward-looking statements within the meaning of Canadian securities
legislation (the “Forward-looking Statements”), including with respect to: the plans of FNDX;
expectations regarding industry trends, including with respect to the antimicrobial surface market,
overall market growth rates and FNDX’s growth rates and growth strategies; that microbe repellent
technology is a promising, high-growth industry; the use of available funds; the performance of FNDX’s
business and operations; FNDX’s expectations regarding revenues, expenses and anticipated cash needs;
the intention to grow FNDX’s business and operations; the expected timing and completion of FNDX’s
nearterm objectives; laws and regulations and any amendments thereto applicable to FNDX; FNDX’s
competitive advantages and business strategies; FNDX’s future product offerings; FNDX’s research and
development initiatives and expected results thereof; FNDX’s growing patent portfolio; FNDX’s ability to
enter into distribution, manufacturing and other business relationships; the potential of FNDX’s
technology to protect against the spread of pathogens on surfaces through repelling bacteria and
viruses that come in contact with its surface; that FNDX’s technology will bring significant value in
controlling the spread of surface borne infectious diseases; that FNDX’s technology could be a key
weapon to contribute in the battle against the growing global threat of infectious disease transmission;
that FNDX’s technology could be deployed all over the world and it could save human lives; that spread
of infectious disease is a deadly problem which is getting worse; that for businesses and governments
looking to mitigate the spread of pathogens, FNDX’s nanotechnology could be part of the answer; if
commercialized, FNDX’s technology could address the urgent need for innovative solutions to help
control the spread of pathogens on surfaces – especially in healthcare; FNDX’s proprietary REPELWRAP™
film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help
prevent pathogen transmission; FNDX’s nanotechnology has the potential to be applied to other types
of surfaces and materials – such as catheters which could significantly help reduce blockages caused by
bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like
this offer potentially future upside, if FNDX can successfully adapt their technology; FNDX’s intention to
initially target REPELWRAP TM film towards healthcare settings and high traffic public touchpoints; that as
FNDX continues its product development, we may see it used to protect surfaces in other high traffic
places like the transportation, sports and entertainment, hospitality, and education sectors; the growing
global commitment to reduce the spread of pathogens; and that REPELWRAP™ film will provide
additional protection to current disinfecting practices to control the spread of pathogens. Although
FNDX believes that such statements are reasonable, it can give no assurance that such expectations will
prove to be correct. Forward-looking statements are statements that are not historical facts; they are
generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,”
“intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar
expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are
those statements, which, by their nature, refer to future events. FNDX cautions that forward-looking
statements are based on the beliefs, estimates and opinions of FNDX’s management on the date the
statements are made and they involve a number of risks and uncertainties. Consequently, there can be
no assurances that such statements will prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these
forward-looking statements include: product candidates only being in formulation/reformulation stages;
limited operating history, no revenues and uncertainty around additional financing; negative cash flow
history; no production history and lack of revenues from sales; no history of manufacturing or
distribution; highly competitive industry; satisfying the terms of the License Agreement and
Collaborative Research Agreement between FNDX and McMaster University and maintaining the License
in good standing; inability of McMaster University to satisfy the terms under the License Agreement and
Collaborative Research Agreement; completion of scale-up and development of a commercial product;
research and development activities; reliance on grant funding; limited number of products;
dependence on collaborative partners, licensors and others; changes and restrictions due to legal and
regulatory requirements; dependence on each product’s acceptance in the market; possibility of smaller
market opportunities than anticipated; increasing regulatory and compliance costs for public companies;
global economic instability; product liability claims and lawsuits; system failures; reliance on
management and loss of key employees or inability to hire key personnel; limited experience of senior
management in managing a public company; fraudulent or illegal activity by employees, contractors and
consultants; inability to effect service of process on some of FNDX’s directors and officers;
management’s efforts and abilities; potential conflicts of interest; inability to protect intellectual
property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary
rights of third parties; risks related to forward-looking information; volatility of the market price of
FNDX’s common shares; potential dilution of the common shares; lack of an active, liquid and orderly
trading market for the common shares; failure of securities or industry analysts to publish research or
publish inaccurate or unfavourable research about FNDX; inability or unwillingness to pay dividends;
exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public
health crisis or another global health pandemic; use of available funds; effect of general economic and
political conditions; internal controls; and other risk factors set forth in FNDX’s final prospectus dated
January 31, 2023 under the heading “Risk Factors” and other filings, publicly available through the
Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at
www.sedar.com. The reader is urged to refer to FNDX’s prospectus and other filings, publicly available
through SEDAR at www.sedar.com for a more complete discussion of such risk factors and their
potential effects. Except to the extent required by applicable securities laws and the policies of the
Canadian Securities Exchange, FNDX undertakes no obligation to update these forward-looking
statements if management’s beliefs, estimates or opinions, or other factors, should change. New factors
emerge from time to time, and it is not possible for FNDX to predict all of them or assess the impact of
each such factor or the extent to which any factor, or combination of factors, may cause results to differ
materially from those contained in any Forward-looking Statement. Any Forward-looking Statements
contained in this article are expressly qualified in their entirety by this cautionary statement.
While the information contained in this article is believed to be accurate, FNDX expressly disclaims any
and all liability for any losses, claims or damages of whatsoever kind based upon the information
contained in, or omissions from, this article or any oral communication transmitted in connection
therewith. In addition, none of the statements contained in this article are intended to be, nor shall be
deemed to be, representations or warranties of FNDX. Where the information is from third-party
sources, the information is from sources believed to be reliable, but FNDX has not independently
verified any of such information contained herein.
This article is not, and under no circumstances is to be construed as, a prospectus, an offering
memorandum, an advertisement or a public offering of securities. Under no circumstances should the
information contained herein be considered an offer to sell or a solicitation of an offer to buy any
securities.
GENERAL DISCLAIMER
Triple Bull Consulting Inc. (“Triple Bull”) and its affiliates or partners will seek to provide
services to companies mentioned on the TheMomentumLeter.com website. Hence, all
information available on TheMomentumLeter.com should be considered as commercial
advertisement and not an endorsement, offer or recommendation to buy or sell
securities. Triple Bull and its related companies (including its directors, employees and
representatives) or a connected person may have ownership/stock positions in, or
options on the securities detailed in this report, and may buy, sell or offer to purchase or
sell such securities from time to time.
Triple Bull and/or its affiliates and/or their respective officers, directors or employees
may from time to time acquire, hold or sell securities and/or commodities and/or
commodity futures contracts in certain underlying companies mentioned in this site and
which may also be clients of Triple Bull’s affiliates. In such instances, Triple Bull and/or
its affiliates and/or their respective officers, directors or employees will use all
reasonable efforts to avoid engaging in activities that would lead to conflicts of interest
and Triple Bull and/or its affiliates will use all reasonable efforts to comply with
conflicts of interest disclosures and regulations to minimize the conflict.
Specifically all companies mentioned or listed as “Sponsored” at
TheMomentumLeter.com. and which are shown under the heading “Sponsored” on the
site have entered into a commercial relationship with Triple Bull or our affiliates for
capital market services and have paid fees and/or shares or stock options or warrants
for being featured and mentioned in TheMomentumLeter.com. Hence these
“Sponsored” at TheMomentumLeter.com are shown at the website as an advertisement
only and any mention of these companies does not and will not constitute an offer to
buy or sell securities in the featured companies. Triple Bull, its affiliates or partners will
seek to provide services to companies mentioned in TheMomentumLeter.com website.
Hence, all information available on TheMomentumLeter.com should be considered as
commercial advertisement and not an endorsement, offer or recommendation to buy or
sell securities.
Triple Bull is not registered with any financial or securities regulatory authority in British
Columbia or Canada, and does not provide nor claims to provide investment advice or
recommendations to any visitor of this site or readers of any content on this site.
The information on this site is for informational purposes only. This site, including the
data, information, research reports, press releases, findings, comments, views and
opinions of Triple Bull’s analysts, columnists, speakers or commentators, and other
contents contained in it, is not intended to be: investment, tax, banking, accounting,
legal, financial or other professional or expert advice of Triple Bull or its affiliates, or a
recommendation, solicitation or offer by Triple Bull or its affiliates to buy or sell any
securities, futures, options or other financial instruments, and such information should
not be relied upon for such advice. Every user of this site is advised to seek professional
advice before acting or omitting to act on any information contained in the site.
Research reports and newsletters have been prepared without reference to any
particular user’s investment requirements or financial situation. Where reference is
made to estimate of value or relative value of a specific company, there is no guarantee
that these estimates are reliable or will materialize. Readers of these reports and
newsletters are advised to conduct their own due diligence before making any
investment decisions. Triple Bull does not make independent investigation or inquiry as
to the accuracy and completeness of any information provided by the “Sponsored”
companies. Although the content has been obtained from sources believed to be
reliable, this website could include technical or other inaccuracies or typographical
errors and it is provided to you on an “as is” basis without warranties or representations
of any kind. Triple Bull and its affiliates make no representation and disclaim all express
and implied warranties and conditions of any kind, including without limitation,
representations, warranties or conditions regarding accuracy, timeliness, completeness,
non-infringement, satisfactory quality, merchantability, merchantable quality or fitness
for any particular purpose or those arising by law, statute, usage of trade, or course of
dealing. Triple Bull and its affiliates assume no responsibility to you or any third party
for the consequences of any errors or omissions.
Information in this site is subject to change without notice. Triple Bull assumes no
liability for any inaccurate, delayed or incomplete information, nor for any actions taken
in reliance thereon.
Triple Bull, its affiliates and their respective directors, officers, employees, or agents
expressly disclaim any liability for losses or damages, whether direct, indirect, special,
or consequential, or other consequences, howsoever caused, arising out of any use or
reproduction of this site or any decision made or action taken in reliance upon the
content of this site, whether authorized or not. By accessing this site, each user of this
site releases Triple Bull, its affiliates and their respective officers, directors, agents and
employees from all claims and proceedings for such losses, damages or
consequences.
Triple Bull and its affiliates do not endorse or recommend any securities issued by any
companies identified on, or linked through, this site. Please seek professional advice to
evaluate specific securities or other content on this site. Links, if any, to third party sites
are for informational purposes only and not for trading purposes. Triple Bull and its
affiliates have not prepared, reviewed or updated any content on third party sites and
assume no responsibility for the information posted on them.
Triple Bull and/or its affiliates and/or their respective officers, directors or employees
may from time to time acquire, hold or sell securities and/or commodities and/or
commodity futures contracts mentioned in this site.
This site may include forward-looking statements about objectives, strategies and
expected financial results of companies featured in this site or where research reports
are available on companies displayed and/or featured on this site. Such forward-looking
statements are inherently subject to uncertainties beyond the control of such
companies. The users of this site are cautioned that the company’s actual performance
could differ materially from such forward-looking statements.
World Wide Web sites accessed by hypertext links (“hyperlinks”) appearing in this site
have been independently developed by parties other than Triple Bull and Triple Bull has
no control over information in any hyperlinked site. Triple Bull is providing hyperlinks to
users of this site only as a convenience. Triple Bull makes no representation and is not
responsible for the quality, content or reliability of any information in any hyperlinked
site. The inclusion of any hyperlink in this site should not be construed as an
endorsement by Triple Bull of the information in such hyperlinked site and does not
imply that Triple Bull has investigated, verified or monitored the information in any such
hyperlinked site. Should you wish to inquire about creating a link from your World Wide
Web site to this site, contact marketing via e-mail at:
marketing@triplebullconsulting.com for written authorization.
Any non-personal communication, comments, ideas or material you post or transmit to
Triple Bull through its website is, and will be treated as, non-confidential and non-
proprietary. By transmitting or posting any communication or material to this web site
you grant to Triple Bull and all of its affiliates, an unrestricted, irrevocable license to use,
reproduce, display, modify, transmit, distribute, publish, broadcast or post your
communication for any purpose. You also agree that Triple Bull is free to use any ideas,
concepts, know-how or techniques that you send us for any purpose through this
website. However, we will not release your name or otherwise publicize the fact that you
submitted materials or other information to us through this website unless:
- you grant us permission to do so;
- we first notify you that the materials or other information you submit to a particular
part of a site will be published or otherwise used with your name on it; or - we are required to do so by law.
I’m sure if it effectively cures or prevents disease on a massive scale it will be bought by Pfizer and Shelved permanently.
I totally agree with Ben. No matter the field whether it is curing cancer or Diabetes in medicine . Or if it is making a better battery system for electric and hybrid cars. Some big company swoops in and buys off the inventor so their product can never make it to light!!!
We are in a major decline in this nation hard work and ingenuity are no longer rewarded like they once were.
I also agree with Ben and L.D. Anything that’s been invented to take away the suffering of humanity will be bought by some greedy corporation like Pfizer and we will never hear of it again. I’m certain there IS a cure for cancer but they won’t allow us to have it because in their sick twisted greedy minds it’s more profitable to keep people sick rather than to cure them. This really infuriates me and it should make us all mad! Imagine yourself or a loved one gets diagnosed with terminal cancer only to find out that there is in fact a cure but Big Pharma won’t allow us to have access to it. So our lives get cut short and we have to live the rest of it in pure misery due to GREED! I hope that these monsters are the 1st to be sent to hell. I’d say more of what I think but I’m sure that my comment will be sensored since I’m telling the truth. Heaven forbid anyone tells the truth anymore. I hate this planet(well,not the planet, but these humans or entities in human form that try to control us all).
Shame on all involved in keeping us sick and hiding cures!
I hear where you’re coming from! And no, not censored….though it would be nice to get your thoughts on the company under consideration here.
I take the George Carlin point of view on people. Love each of them and often have a strong distaste for groups of them – groups meaning 2+ 🙂
True. They will develop cures for themselves and disease and control for the rest of us. Itsa brave new world
Nano technology cant much yet. So far it hasn’t cured anything. Trying to repair the he damage alzymers gives to the brains hypocampus is like trying to repair an old elivis Presley record that has already been scratched!
I share your frustration in this regard. However the technology in question here is not a cure at all but rather a preventative measure.
It’s terrible how it’s plainly obvious to everyone that these big companies will come in buy everything and stop progress to make society better. We the people need to rebel against these companies and demand justice for society.
I agree with all of you guys. We need to organize some how . They have purposely scattered us and our beliefs so that public humiliation. Has made us all clowns to the truth we need to stand up for. We can’t let them do this anymore why can’t we stop them. Their evil runs deep, far back from our past. So many people involved in their scheme many unknowingly brainwashed since birth, raised in an evil biased plan. It’s sounds nuts but it is true. The bible is the way to the light of truth. Stand firm with God Jesus by your side let the Holy Spirit work through you and use the bible as your shield from evil. Do as Jesus would do walk in his light to save life in this world. Heat brings heat and evil begets evil. Bye the blood of Jesus, Satan get behind thee.
Barbara, you are right! We have to start using what God gave us. Herbs. God the holistic route.
Look up Barbara O’Neill video’s. We don’t need the drugs…
These monster companies like phyzer need to be broken up into smaller companies and never allowed to become large and more powerful than government ever again!
Just shows money and control over Us is more important than saving Us. Prisons make $70-$80 Billions Dollars a year in the USA alone. Which President will care for us and the “elite”?
J…..How do prisons make billions?
They do it because nobody has the guts to fight them not to many men left! Lot of them are in prison! I’m a firm believer that if they came from house to house to kill everyone’s first born child that very few people would fight back too many football games and new movies to watch and don’t forget that trip to Las Vegas this year and we want to buy a new summer home in Florida! People will fight back when it’s too late!
Amen to all of your comments. You hit the nail, truth right on the head